Targeting a specific pathway in neutrophils to treat deep vein thrombosis.
Treatment of Deep Vein Thrombosis via Targeted Inhibition of the FXII-uPAR-pAkt2 Axis in Neutrophils
This study is testing a new treatment for deep vein thrombosis (DVT) that aims to reduce blood clot formation by targeting certain cells in your body, and it hopes to offer a safer option than current blood thinners that can cause bleeding.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Louis Stokes Cleveland VA Medical Center NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10516085 on NIH RePORTER |
What this research studies
This research aims to develop a new treatment for deep vein thrombosis (DVT) by targeting a specific interaction between coagulation factor FXII and a receptor called uPAR in neutrophils. The approach focuses on reducing the activation of neutrophils, which play a significant role in the formation of blood clots. By using a nanomedicine-based strategy, the researchers hope to prevent harmful processes that contribute to DVT, such as the formation of neutrophil extracellular traps. This innovative method seeks to provide a safer alternative to current anticoagulant therapies that often lead to increased bleeding risks.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with deep vein thrombosis who may benefit from new therapeutic options.
Not a fit: Patients who do not have deep vein thrombosis or those who are not responsive to anticoagulant therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safer and more effective treatment for patients suffering from deep vein thrombosis.
How similar studies have performed: While there have been advancements in anticoagulant therapies, this specific approach targeting the FXII-uPAR-pAkt2 axis in neutrophils is novel and has not been extensively tested in prior studies.
Where this research is happening
Cleveland, United States
- Louis Stokes Cleveland VA Medical Center — Cleveland, United States (Active)
Researchers
- Principal investigator: Stavrou, Evi X. — Louis Stokes Cleveland VA Medical Center
- Study coordinator: Stavrou, Evi X.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.